アブストラクト
Japanese
| Title | オビヌツズマブ投与時におけるinfusion reaction発現に影響を与える因子の探索 |
|---|---|
| Subtitle | ノート |
| Authors | 黒松誠1, 梶田貴司1, 樽野麻依1, 西川豊1, 赤坂尚司2, 奥野智之1 |
| Authors (kana) | |
| Organization | 1公益財団法人天理よろづ相談所病院薬剤部, 2血液内科 |
| Journal | 医療薬学 |
| Volume | 47 |
| Number | 11 |
| Page | 631-638 |
| Year/Month | 2021 / 11 |
| Article | 報告 |
| Publisher | 日本医療薬学会 |
| Abstract | 「緒言」非ホジキンリンパ腫のうち, B細胞リンパ腫は細胞表面にCD20を発現しており, これを標的とした抗CD20モノクローナル抗体であるリツキシマブが開発されて以降, B細胞リンパ腫の治療成績は飛躍的に向上した. しかし, リツキシマブ併用化学療法に治療抵抗性を示す症例が病型によらず存在し, リツキシマブを上まわる効果をもつ抗CD20モノクローナル抗体の開発が望まれてきた. 近年, 新規抗体改変技術を用いたFc領域の糖鎖改変により直接的な細胞死の誘導活性, 抗体依存性細胞傷害(antibody dependent cellular cytotoxicity: ADCC)および抗体依存性細胞貪食(antibody dependent cell mediated phagocytosis: ADCP)活性を高めた新規抗CD20モノクローナル抗体であるオビヌツズマブが開発された. 濾胞性リンパ腫患者を対象とした国際共同第III相臨床試験(GALLIUM 試験)において, オビヌツズマブ + 化学療法(G群)とリツキシマブ + 化学療法(R群)の有効性が比較され, R群に対するG群の有意な無増悪生存期間の延長を認めた一方, 有害事象の頻度はR群に比べG群で高かった. |
| Practice | 薬学 |
| Keywords | obinutuzumab, infusion reactions, risk factor, soluble interleukin-2 receptor, lactate dehydrogenase |
English
| Title | Search for Risk Factors Influencing the Occurrence of Infusion Reaction after Initial Treatment with Obinutuzumab |
|---|---|
| Subtitle | Notes |
| Authors | Makoto Kuromatsu1, Takashi Kajita1, Mai Taruno1, Yutaka Nishikawa1, Takashi Akasaka2, Tomoyuki Okuno1 |
| Authors (kana) | |
| Organization | 1Department of Pharmacy, 2Department of Hematology Tenri Hospital |
| Journal | Japanese Journal of Pharmaceutical Health Care and Sciences |
| Volume | 47 |
| Number | 11 |
| Page | 631-638 |
| Year/Month | 2021 / 11 |
| Article | Report |
| Publisher | Japanese Society of Pharmaceutical Health Care and Sciences |
| Abstract | Obinutuzumab, a novel glyco-engineered anti-CD20 monoclonal antibody, has been developed to have superior efficacy to rituximab. Although obinutuzumab frequently causes infusion reactions (IR) during initial administration, there have been few reports about the frequency and risk factors for IR. In this study, we investigated the frequency of clinically relevant IR during obinutuzumab administration and explored the risk factors associated with obinutuzumab-induced IR. We included patients who were administered obinutuzumab for CD20+ B-cell non-Hodgkin lymphoma treatment at the Department of Hematology in Tenri Hospital from September 2018 to September 2020. Twenty-five patients were included (13 men and 12 women) and their median age was 68 (49 - 81 years). Nine (36%) of these patients developed IR (grade >= 2). Comparison of patient characteristics between IR and non-IR groups showed that the incidence of IR during obinutuzumab administration was related to soluble interleukin-2 receptor (sIL-2R) and lactate dehydrogenase (LDH) levels. The results of ROC curve analysis revealed the cut-off values of sIL-2R and LDH were 3,201 U/mL and 260 U/L, respectively, and AUC of ROC curve for sIL-2R and LDH were estimated at 0.75 and 0.72, respectively. The higher IR incidence was detected when sIL-2R levels exceeded 3,201 U/mL. In addition, the number of patients who developed IR at sIL-2R >= 3,201 U/mL and/or LDH >= 260 U/L was larger than that at sIL-2R >= 3,201 U/mL. The combined biomarker, sIL-2R and LDH may be useful for prediction of the occurrence of IR after the initial administration of obinutuzumab. |
| Practice | Pharmaceutical sciences |
| Keywords | obinutuzumab, infusion reactions, risk factor, soluble interleukin-2 receptor, lactate dehydrogenase |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R, IDEC-C2B8(Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma, Blood, 1997, 90, 2188-2195.
- 2) Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, Lopez-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M, MabThera International Trial Group, CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with goodprognosis diffuse large-B-cell lymphoma:a randomised controlled trial by the MabThera International Trial(MInT) Group, Lancet Oncol, 2006, 7, 379-391.
- 3) Maloney DG, Anti-CD20 antibody therapy for B-cell lymphomas, N Engl J Med, 2012, 366, 2008-2016.
- 4) Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, Phillips E, Sangha R, Schlag R, Seymour JF, Townsend W, Trneny M, Wenger M, Fingerle-Rowson G, Rufibach K, Moore T, Herold M, Hiddemann W, Obinutuzumab for the First-Line Treatment of Follicular Lymphoma, N Engl J Med, 2017, 377, 1331-1344.
- 5) Kanda Y, Investigation of the freely available easy to-use software 'EZR' for medical statistics, Bone Marrow Transplant, 2013, 48, 452-458.
残りの8件を表示する
- 6) Kitagawa J, Hara T, Tsurumi H, Goto N, Kanemura N, Yoshikawa T, Kasahara S, Yamada T, Sawada M, Takahashi T, Shimizu M, Takami T, Moriwaki H, Serum-soluble interleukin-2 receptor(sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified(PTCL-U), J Cancer Res Clin Oncol, 2009, 135, 53-59.
- 7) Goto H, Tsurumi H, Takemura M, Ino-Shimomura Y, Kasahara S, Sawada M, Yamada T, Hara T, Fukuno K, Goto N, Okuno M, Takami T, Seishima M, Moriwaki H, Serum-soluble interleukin-2 receptor(sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma:in combination with the International Prognostic Index, J Cancer Res Clin Oncol, 2005, 131, 73-79.
- 8) Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, Gascoyne RD, Connors JM, The revised International Prognostic Index(R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP, Blood, 2007, 109, 1857-1861.
- 9) Snowden A, Hayden I, Dixon J, Gregory G, Prevention and management of obinutuzumab-associated toxicities:Australian experience, Int J Nurs Pract, 2015, 21, 15-27.
- 10) 安田昌宏, 舘 知也, 梅田 道, 臼井一将, 長屋雄大, 大澤友裕, 市橋厚司, 後藤英子, 笠原千嗣, 高橋 健, 寺町ひとみ, 後藤千寿, Rituximab初回投与時におけるInfusion Reaction発現に影響を与える因子の解明, 癌と化学療法, 2014, 41, 975-979.
- 11) Hayama T, Miura K, Uchiike A, Nakagawa M, Tsutsumi D, Sakagami M, Yoshida Y, Takei M, A clinical prediction model for infusion-related reactions to rituximab in patients with B cell lymphomas, Int J Clin Pharm, 2017, 39, 380-385.
- 12) Hong J, Kim JY, Ahn HK, Lee SM, Sym SJ, Park J, Cho EK, Ahn JY, Park S, Lee SP, Shin DB, Lee JH, Bone marrow involvement is predictive of infusion related reaction during rituximab administration in patients with B cell lymphoma, Support Care Cancer, 2013, 21, 1145-1152.
- 13) Cho KM, Keam B, Ha H, Kim M, Jung JW, Song WJ, Kim TM, Jeon YK, Kang HR, Kim DW, Kim CW, Heo DS, Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP, Korean J Intern Med, 2017, 20, 1-9.
